Renal cell carcinoma · 3 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Sunitinib monotherapy Variant #05 | — | R 33 433 | 28d | ~9.2 mo | — | ~11 | ~R 367 764 PFS proxy · indirect | 2 |
Observation Partial | — | — | — | — | — | — | — | 2 |
Placebo Partial | — | — | — | — | — | — | — | 1 |
3 of 3 regimens shown